目的 探讨凝血功能障碍对儿童噬血细胞综合征（HPS）预后的影响及意义。方法 回顾性分析35例HPS患儿的病因、临床特征、实验室检查结果及治疗转归情况。结果 35例HPS患儿经治疗后，27例存活，8例死亡。其中25例严格按照HLH-2004方案治疗，10例除未使用依托泊甙（VP-16）外，其余治疗方案均按HLH-2004治疗方案进行，使用VP-16治疗的患儿有效率（22/25，88%）高于未使用VP-16患儿（5/10，50%）（P<0.05）。死亡组血小板计数、纤维蛋白原水平和VP-16使用率均低于存活组，而活化部分凝血酶时间和凝血酶原时间均高于存活组（均P<0.05）。结论 凝血功能可做为评估HPS转归的一项指标，治疗过程中监测凝血功能，早期发现异常，及时纠正并严格按照HLH-2004方案正规治疗对改善HPS临床预后至关重要。
Abstract
Objective To study the prognostic significance of coagulation disorders in children with hemophagocytic syndrome (HPS). Methods Thirty-five children with HPS were retrospectively studied to analyze the etiology, clinical characteristics, laboratory results and treatment outcomes. Results After treatment, 27 of the 35 HPS patients survived, and the other 8 cases died. All cases were treated according to the HLH-2004 protocol, but etoposide (VP-16) was not used in 10 of them. The response rate in patients who received VP-16 (22/25, 88%) was significantly higher than that in those not receiving VP-16 (5/10, 50%) (P<0.05). Compared with the survival group, the dead group had significantly lower platelet count, fibrinogen level, and VP-16 utilization rate (P<0.05) but significantly longer activated partial thromboplastin time and prothrombin time (P<0.05). Conclusions Coagulation function can be used as an indicator of disease outcome. It is essential for improving the clinical outcome of HPS to monitor the coagulation function during treatment, detect and correct abnormalities in time, and provide treatment strictly according to the HLH-2004 protocol.
关键词
噬血细胞综合征 /
凝血功能 /
儿童
Key words
Hemophagocytic syndrome /
Coagulation function /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Bhattacharyya M, Ghosh MK. Hemophagoctic lymphohistiocytosis-recent concept[J]. J Assoc Physicians India, 2008, 56: 453-457.
[2] 闫丽娟, 王昭. 噬血细胞综合征继发凝血功能障碍的认识与研究[J]. 临床和实验医学杂志, 2012, 11(2): 142-143.
[3] 肖莉, 宪莹, 戴碧涛, 等. HLH-2004方案治疗83例EB病毒相关噬血淋巴组织细胞增生症患儿疗效分析[J]. 中华血液学杂志, 2011, 32(10): 668-672.
[4] 王华, 高文瑾, 刘安生, 等. 儿童噬血细胞综合征54例临床及预后因素分析[J]. 中国小儿血液与肿瘤杂志, 2013, 18(1): 31-34.
[5] Tseng YT, Sheng WH, Lin BH, et al. Causes, clinical symptoms,and outcomes of infectious disease associated with hemophagocytic lymphohistiocytosis in Taiwanese adults[J]. Microbiol Immunol Infect, 2011, 44(3): 191-197.
[6] Karapinar B, Yilmaz D, Balkan C. An unusual cause of multiple organ dysfunction syndrome in the pediatric intensive care unit : hemophagocytic lymphohistiocytosis[J]. Pediatr Crit Care Med, 2009, 10(3): 285-290.
[7] 中华医学会儿科学分会血液学组. 噬血细胞性淋巴组织细胞增生症诊疗建议[J]. 中华儿科杂志, 2012, 50(11): 821-825.
[8] 汤静燕, 李志光. 儿童肿瘤诊断与治疗学[M]. 北京: 人民军医出版社, 2011: 282-289.
[9] Ansuini V, Donato R, Esposito S. Debate around infection-dependent hemophayocytic syndrome in paediatrics[J]. BMC Infection Diseases, 2013, 16(1): 13-15.
[10] 孙雪辉, 郑文浩, 张文, 等. 自身免疫病合并噬血细胞综合征临床分析[J]. 中华内科杂志, 2010, 49(10): 836-840.
[11] 王旖旎, 王昭, 吴林. 多中心72例噬血细胞综合征诊疗分析[J]. 中华血液学杂志, 2009, 30(12): 793-798.
[12] 郭子雄, 钟敏泉, 翟琼香, 等. 小儿噬血细胞综合征合并多脏器功能不全临床特征研究[J].中华临床医师杂志, 2011, 5(8): 2374-2377.
[13] Zhuang JL, Jiang QW, Xu Y, et al. Recombinant activated factor Ⅶ in hemophagocytic lymphohistiocytosis with disseminated intravascular coagulation[J]. Chin Med J(Engl), 2011, 124(19): 3189-3191.
[14] Yamamoto M, Hori T, Hatakeyama N, et al. Use of recombinant thrombomodulin in disseminated intravascular cogulation complicated hemophagocytic lymphohistiocytosis[J]. Indian J Pediatr, 2014, 81(3): 288-291.
[15] Janka GE. Hemophagocytic lymphohistiocytosis[J]. Blood Rev, 2007, 21(5): 245-253.
[16] 李小琳, 刘玉玲, 付四毛. 儿童噬血细胞综合征32例临床分析[J]. 中国小儿急救医学, 2012, 9(1): 38-40.
PDF(1376 KB)
